Medtronic Vitatron digital pacemakers:
This article was originally published in Clinica
Medtronic has received US market approval for its Vitatron T-series of digital pacemakers. Digital technology enables the T-series devices to collect heart rate information more quickly and precisely than other pacemakers, the company claimed. This can help physicians better understand the patient's heart condition and confidently apply appropriate pacemaker and drug therapies, the company claimed. The efficiency gains of digital data collection also contribute to the T-series' expected long lifespan of 9.3 years. The devices were developed by Medtronic's European subsidiary, Vitatron.
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.